This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It

Revolution Medicines, a pre-revenue biotech company developing targeted cancer treatments to replace chemotherapy, has surged 125% in 2026. The company's flagship drug Daraxonrasib received FDA Breakthrough Therapy designation and is undergoing accelerated review by the EMA. Billionaire Stanley Druckenmiller's Duquesne Family Office purchased 316,000 shares worth $30.6 million in Q1 2026, now valued at $56.6 million, signaling confidence in the company's potential despite its speculative nature.